A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema
Abstract Background This meta-analysis evaluated the effectiveness and safety of dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME). Methods The PubMed, Embase, clinicaltrials.gov website and Cochrane Library databas...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-05-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12886-018-0779-1 |
| _version_ | 1818450789325078528 |
|---|---|
| author | Ye He Xin-jun Ren Bo-jie Hu Wai-Ching Lam Xiao-rong Li |
| author_facet | Ye He Xin-jun Ren Bo-jie Hu Wai-Ching Lam Xiao-rong Li |
| author_sort | Ye He |
| collection | DOAJ |
| description | Abstract Background This meta-analysis evaluated the effectiveness and safety of dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME). Methods The PubMed, Embase, clinicaltrials.gov website and Cochrane Library databases were comprehensively searched for studies comparing DEX implant with anti-VEGF in patients with DME. Best-corrected visual acuity (BCVA), central subfield thickness (CST) and adverse events were extracted from the final eligible studies. Review Manager (RevMan) 5.3 for Mac was used to analyze the data and GRADE profiler were used to access the quality of outcomes. Results Based on four randomized clinical trials assessing a total of 521 eyes, the DEX implant can achieve visual acuity improvement for DME at rates similar to those achieved via anti-VEGF treatment (mean difference [MD] = − 0.43, P = 0.35), with superior anatomic outcomes at 6 months (MD = − 86.71 μm, P = 0.02), while requiring fewer injections, in comparison to anti-VEGF treatment. Although the mean reduction in CST did not showed significant difference at 12 months (MD = − 33.77 μm, P = 0.21), the significant in BCVA from baseline to 12 months supported the anti-VEGF treatment (MD = − 3.26, P < 0.00001). No statistically significant differences in terms of the serious adverse events. However, use of the DEX implant has higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment. Conclusions Compared with anti-VEGF, DEX implant improved anatomical outcomes significantly. However, this did not translate to improved visual acuity, which may be due to the progression of cataract. Therefore, the DEX implant may be recommended as a first chioce for select cases, such as for pseudophakic eyes, anti-VEGF-resistant eyes, or patients reluctant to receive intravitreal injections frequently. |
| first_indexed | 2024-12-14T20:56:53Z |
| format | Article |
| id | doaj.art-d367cf1c71af4b6dbe372709896af07c |
| institution | Directory Open Access Journal |
| issn | 1471-2415 |
| language | English |
| last_indexed | 2024-12-14T20:56:53Z |
| publishDate | 2018-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj.art-d367cf1c71af4b6dbe372709896af07c2022-12-21T22:47:41ZengBMCBMC Ophthalmology1471-24152018-05-0118111110.1186/s12886-018-0779-1A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edemaYe He0Xin-jun Ren1Bo-jie Hu2Wai-Ching Lam3Xiao-rong Li4Department of Retina, Tianjin Medical University Eye HospitalDepartment of Retina, Tianjin Medical University Eye HospitalDepartment of Retina, Tianjin Medical University Eye HospitalDepartment of Ophthalmology, The University of Hong KongDepartment of Retina, Tianjin Medical University Eye HospitalAbstract Background This meta-analysis evaluated the effectiveness and safety of dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME). Methods The PubMed, Embase, clinicaltrials.gov website and Cochrane Library databases were comprehensively searched for studies comparing DEX implant with anti-VEGF in patients with DME. Best-corrected visual acuity (BCVA), central subfield thickness (CST) and adverse events were extracted from the final eligible studies. Review Manager (RevMan) 5.3 for Mac was used to analyze the data and GRADE profiler were used to access the quality of outcomes. Results Based on four randomized clinical trials assessing a total of 521 eyes, the DEX implant can achieve visual acuity improvement for DME at rates similar to those achieved via anti-VEGF treatment (mean difference [MD] = − 0.43, P = 0.35), with superior anatomic outcomes at 6 months (MD = − 86.71 μm, P = 0.02), while requiring fewer injections, in comparison to anti-VEGF treatment. Although the mean reduction in CST did not showed significant difference at 12 months (MD = − 33.77 μm, P = 0.21), the significant in BCVA from baseline to 12 months supported the anti-VEGF treatment (MD = − 3.26, P < 0.00001). No statistically significant differences in terms of the serious adverse events. However, use of the DEX implant has higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment. Conclusions Compared with anti-VEGF, DEX implant improved anatomical outcomes significantly. However, this did not translate to improved visual acuity, which may be due to the progression of cataract. Therefore, the DEX implant may be recommended as a first chioce for select cases, such as for pseudophakic eyes, anti-VEGF-resistant eyes, or patients reluctant to receive intravitreal injections frequently.http://link.springer.com/article/10.1186/s12886-018-0779-1Diabetic macular edemaOzurdexDexamethasone implantAnti-VEGFMeta-analysis |
| spellingShingle | Ye He Xin-jun Ren Bo-jie Hu Wai-Ching Lam Xiao-rong Li A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema BMC Ophthalmology Diabetic macular edema Ozurdex Dexamethasone implant Anti-VEGF Meta-analysis |
| title | A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema |
| title_full | A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema |
| title_fullStr | A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema |
| title_full_unstemmed | A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema |
| title_short | A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema |
| title_sort | meta analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti vascular endothelial growth factor treatment for diabetic macular edema |
| topic | Diabetic macular edema Ozurdex Dexamethasone implant Anti-VEGF Meta-analysis |
| url | http://link.springer.com/article/10.1186/s12886-018-0779-1 |
| work_keys_str_mv | AT yehe ametaanalysisoftheeffectofadexamethasoneintravitrealimplantversusintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedema AT xinjunren ametaanalysisoftheeffectofadexamethasoneintravitrealimplantversusintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedema AT bojiehu ametaanalysisoftheeffectofadexamethasoneintravitrealimplantversusintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedema AT waichinglam ametaanalysisoftheeffectofadexamethasoneintravitrealimplantversusintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedema AT xiaorongli ametaanalysisoftheeffectofadexamethasoneintravitrealimplantversusintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedema AT yehe metaanalysisoftheeffectofadexamethasoneintravitrealimplantversusintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedema AT xinjunren metaanalysisoftheeffectofadexamethasoneintravitrealimplantversusintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedema AT bojiehu metaanalysisoftheeffectofadexamethasoneintravitrealimplantversusintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedema AT waichinglam metaanalysisoftheeffectofadexamethasoneintravitrealimplantversusintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedema AT xiaorongli metaanalysisoftheeffectofadexamethasoneintravitrealimplantversusintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedema |